Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
Bladder Cancer Stage IV
DRUG: Chidamide
Objective Response Rate（ORR）, Objective Response Rate（ORR）by RECIST 1.1,the total proportion of patients with complete response（CR）, partial response（PR）, up to 2 years
Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and Stable Disease（SD）, up to 2 years|Progression-free survival(PFS), Time from treatment until disease progression or death, up to 2 years|Overall survival(OS), Time from treatment until death from any cause, up to 2 years
Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China (Chidamide,a novel histone deacetylase inhibitor). Tirelizumab,has been approved for the failure treatment of platinum-containing chemotherapy with high PD-L1 expression included locally advanced or metastatic Urothelial carcinoma in China(Tirelizumab,BGB-A317 is an investigational humanized IgG4 anti-PD-1 monoclonal antibody ).The aim of this study was to observe the efficacy and safety of Chidamide with Immunotherapy in patients with progression of platinum-based chemotherapy recurrent and metastatic Urothelial carcinoma.